SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (760)6/20/2001 12:18:38 AM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 1834
 
NBIX has solid intellectual right on MCH/MSH/POMC/ACTH hormones family and its receptors, from Salk and Oregon. That others are entering this field is conformation of the field importance and value.

In regards the MCH receptors, SNAP has patent on MCH1, while Merck has EU patent on MCH2. It will be interesting to see what will Tularik do. Point is, solid patents do give advantage.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News